

PATENT Attorney Docket No. **P07181US00** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:

AGGER, Nicolai

SERIAL NO:

10/532,698

FILED:

April 26, 2005

TITLE:

COMPOSITION FOR TREATMENT OF GASTROINTESTINAL

**DISORDERS** 

## INFORMATION DISCLOSURE STATEMENT FILED WITHIN THREE MONTHS OF FILING OR BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. § 1.97(b))

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

This information disclosure statement is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office Action on the merits, or before the mailing of a first office action after the filing of a request for continued examination, whichever event occurs last.

Attached are Forms PTO/SB/08B (formerly Form PTO-1449) listing the relevant art known to the applicant herein. Copies of non-U.S. patents are enclosed. References that are U.S. patents are not required to be submitted. The Examiner is requested to consider the references and make them of record.

CERTIFICATE OF MAILING/TRANSMISSION (37 CFR 1.8(a))

I hereby certify that this correspondence is, on the date shown below, being:

**MAILING** 

☑ deposited with the United States Postal Service with sufficient postage as First Class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: Allywat ( 1000-

FACSIMILE

☐ transmitted by facsimile to the Patent and Trademark Office, Art Unit \_\_\_\_\_

at Fax No. (571) 273-8300

Edmund L Sease

Applicant discloses herewith patents, publications or other information, of which he is aware that he believes may be material to the examination of this application, and in respect of which, there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. § 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner.

Respectfully submitted,

EDMUND J. SEASE, Reg. No. 24,741

McKEE, VOORHEES & SEASE, P.L.C.

801 Grand Avenue, Suite 3200 Des Moines, Iowa 50309-2721

Phone No. (515) 288-3667

Fax No. (515) 288-1338

**CUSTOMER NO: 22885** 

- bja-

Attorneys of Record

Form PTO/SA08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitu	ite for form 1449	PA/PTO			Complete if Known		
				Application Number	10/532,698		
INFO	RMATION	DISCL	OSURE	Filing Date	April 26, 2005		
	EMENT BY			First Named Inventor	AGGER, Nicolai		
01711				Art Unit			
(Us	e as many shee	ts as nec	essary)	Examiner Name			
Sheet	1	of	2	Attorney Docket Number	P07181US0		

			U.S. PA	TENT DOCUMENTS	
Examiner Initials *	Cite No.1	Document Number  Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	US- 3,449,492	06/10/1969	Jensen, Erik H.	
	2	US- 3,989,328	08/05/1975	Beigler et al.	
	3	US- 4,164,568	08/14/1979	Bywater	
	4	US- 4,711,780	12/08/1987	Fahim	
	5	US- 4,839,171	06/13/1989	Nelson	
	6	US- 5,038,396	08/06/1991	Gjerlov	
	7	US- 6,066,341	05/23/2000	Wilson	
·	8	US - 6,007,808	12/28/1999	De Haen et al.	
	9	US- 6,365,176 B1	04/02/2002	Bell et al.	
	10	US- 6,391,310 B1	05/21/2002	Empie et al.	
		US-			

		FOREIG	N PATENT DOC	UMENTS		
Examiner Initials *	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	11	WO 2004/043451 A1	05/27/2004	Phar-Malett A/S		
	12	PA 2002 01736	06/18/2003	Baggrunds Teknik		
	13	WO 98/42188	10/01/1998	Squires, Meryl		
	14	HU61474	1993	Antal, L., et al.		
	15	0 474 282 B1	03/11/1992	Pharmalett International		
	16	0 382 306 A1	08/16/1990	Duphar International		-
	17	WO 85/01441	04/11/1985	GJERLØV, Mogens		
	18	WO 82/ 02650	08/19/1982	Von MAGIUS Niels		
	19	German 2611979	03/19/1976	Mayer, Alois		

The state of the s		
Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in

conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional)... 2 See Kinds of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

<sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Form PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute	e for form 1449B	/PTO		Complete if Known		
				Application Number	10/532,698	
INFOR	RMATION E	DISCL	OSURE	Filing Date	April 26, 2005	
	EMENT BY			First Named Inventor	AGGER, Nicolai	
017(11		,	2.07	Group Art Unit		
(Use	e as many sheets	s as nece	ssary)	Examiner Name		
Sheet	2	of	2	Attorney Docket Number	P07181US0	

	OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²			
	20	Argenzio, Robert A., et al. "Glutamine Stimulates Prostaglandin-Sensitive Na <sup>+</sup> -H <sup>+</sup> Exchange in Experimental Procine Cryptosporidiosis" Gastroenterology 1004;106:1418-1428				
	21	Brooks, H.W., et al. "Evaluation of a Glutamine-containing Oral Rehydration Solution for the Treatment of Calf Diarrhoea using an <i>Escherichia coli</i> Model" The Veterinary Journal 1997, 153, 163-170				
	22	Fettman, Martin J., et al. "Potential Benefits of Psyllium Mucilloid Supplementation of Oral Replacement Formulas for Neonatal Calf Scours" Compedium on Continuing Education for the Practicing Veterinarian, Vol. 14, No. 2, February 1992 247				
	23	Grady, Kevin, "How Basal Media Provide the Optimal Environment for Cell Culture" FOCUS (1999) Vol. 21, No. 3				
	24	Hunt, L., et al. "GFP-Expressing Mammalian Cells for Fast, Sensitive, Noninvasive Cell Growth Assessment in a Kinetic Mode" 1999 John Wiley & Sons, Inc., CCC 0006-3592/99/020201-05				
	25	Naylor, J.M., "Effect of Glutamine or Glycine Containing Oral Electrolyte Solutions on Mucosal Morphology, Clinical and Biochemical Findings, in Calves with Viral Induced Diarrhea" Can J Vet Res 1997; 61:43-48				
	26	http://ohly.de/sommer.htm Yeast Extracts: Production, Properties and Components; 6 pages				
	27	Antibiotics http://www.euroclone.net/cell_biology/celb_ccult_ancil.htm 4/11/2002; 5 pages				
	28	Cell Culture Media Formulations Medium; CMRL Media; 9 pages				
	_					

Examiner	Date	
Signature	Considered	

<sup>\*</sup> EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.